Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists may leads to higher bleeding ‐ major Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Bleeding ‐ clinically indicated non‐major Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Major VTE events in TKR combined doses bilateral ascending venography · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events in TKR combined doses bilateral ascending venography compared with vitamin K antagonists (low certainty).
1 finding from 1 review
All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
Total Bleeding events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in ALT >3 times the upper normal limit at the end of compared with vitamin K antagonists (low certainty).
1 finding from 1 review
Intervention not reported
Stroke and other systemic embolic events · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower stroke and other systemic embolic events (high certainty).
1 finding from 1 review
Intervention not reported
All strokes · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower all strokes (high certainty).
1 finding from 1 review
Intervention not reported
Major bleedings · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower major bleedings (moderate certainty).
1 finding from 1 review
Intervention not reported
Intracranial haemorrhages · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower intracranial haemorrhages (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause deaths · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower all‐cause deaths (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review
Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of recurrent VTE · patients with venous thromboembolism
The intervention leads to lower incidence of recurrent VTE (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of major bleeding · patients with venous thromboembolism
The intervention probably leads to higher incidence of major bleeding (moderate certainty).
1 finding from 1 review